Valuation: vTv Therapeutics Inc.

Market Cap 261M 234M 214M 196M 368M 24.56B 380M 2.58B 1.03B 13.11B 981M 960M 41.37B P/E 2026 *
-9.78x
P/E 2027 * -5.03x
Enterprise Value 261M 234M 214M 196M 368M 24.56B 380M 2.58B 1.03B 13.11B 981M 960M 41.37B EV / Sales 2026 *
8.5x
EV / Sales 2027 * -
Free-Float
61.17%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: vTv Therapeutics Inc.

1 day-3.27%
1 week-16.45%
Current month-16.45%
1 month-29.97%
3 months-39.24%
6 months-33.62%
Current year-47.41%
1 week 20.56
Extreme 20.56
25.26
1 month 20.56
Extreme 20.56
31.22
Current year 20.56
Extreme 20.56
44
1 year 20.56
Extreme 20.56
44
3 years 7.38
Extreme 7.38
44
5 years 7.38
Extreme 7.38
62.4
10 years 7.38
Extreme 7.38
336
Manager TitleAgeSince
Chief Executive Officer 68 2022-07-31
Director of Finance/CFO 50 2025-05-18
Chief Tech/Sci/R&D Officer - 2023-11-01
Director TitleAgeSince
Director/Board Member 56 2020-11-15
Director/Board Member 48 2022-07-10
Chairman 68 2024-02-29
Date Insider Type Main position Quantity % Market Cap. Importance
6/26/26 Free

Director

6,000 0.1523%
2/17/26 Free

Chief Financial Officer

44,969 1.1419%
2/17/26 Free

Chief Executive Officer

140,000 3.5551%
Change 5-day change 1-year change 3-year change Capi.($)
-3.27%-16.45%-17.43%+37.63% 261M
-4.83%+3.51%+53.62%+61.75% 65.94B
-1.34%+2.98%+24.79%+100.18% 56.53B
+0.02%+1.07%+10.63%+76.66% 56.88B
+5.09%+9.89%+22.45%+107.48% 46.49B
+2.62%+1.68%+28.91%+37.01% 44.8B
+8.24%+0.51%+213.26%+792.66% 41.59B
-1.86%+10.13%+26.82%+53.22% 35.35B
-2.97%-9.84%+88.86%+76.17% 33.29B
-2.18%+7.06%+36.06%-4.95% 24.92B
Average -0.05%+1.28%+48.80%+133.78% 40.6B
Weighted average by Cap. +0.21%+3.39%+53.07%+142.89%

Financials

2026 *2027 *
Net sales 30.73M 27.56M 25.19M 23M 43.33M 2.89B 44.69M 304M 121M 1.54B 115M 113M 4.87B -
Net income -21.58M -19.36M -17.69M -16.15M -30.43M -2.03B -31.39M -213M -85.03M -1.08B -81.01M -79.28M -3.42B -64.85M -58.17M -53.16M -48.53M -91.43M -6.1B -94.31M -641M -256M -3.25B -243M -238M -10.27B
Net Debt - -
Projected Income Statement - Annual - vTv Therapeutics Inc.
Logo vTv Therapeutics Inc.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
Employees
26
Date Price Change Volume
26-11-06 US$21.03 -3.27% 14,366
26-11-05 US$21.74 -9.53% 17,776
26-11-04 US$24.03 +2.04% 28,579
26-11-03 US$23.55 -2.48% 37,930
26-11-02 US$24.15 -4.05% 20,788
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - vTv Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
21.03USD
Average target price
56.00USD
Spread / Average Target
+166.29%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - vTv Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. VTVT Stock